导航切换
中国神经再生研究(英文版)
首页
关于本刊
编 委 会
在线投稿
期刊公告
出版道德
OA政策
联系我们
ENGLISH
INRS
数据库
神经退行性病
1.
Emodin attenuates inflammation and demyelination in experimental autoimmune encephalomyelitis
(2023-01-12)
2.
A candidate protective factor in amyotrophic lateral sclerosis: heterogenous nuclear ribonucleoprotein G
(2023-01-12)
3.
Overexpression of fibroblast growth factor 13 ameliorates amyloid-β-induced neuronal damage
(2023-01-05)
4.
The relationship among amyloid-β deposition, sphingomyelin level, and the expression and function of P-glycoprotein in Alzheimer’s disease pathological process
(2023-01-05)
5.
Neural regeneration research model to be explored: SH-SY5Y human neuroblastoma cells
(2023-01-05)
6.
Blunt dopamine transmission due to decreased GDNF in the PFC evokes cognitive impairment in Parkinson’s disease
(2022-11-01)
7.
Neuroprotective effects of insulin-like growth factor-2 in 6-hydroxydopamine-induced cellular and mouse models of Parkinson’s disease
(2022-11-01)
8.
Neural progenitor cells derived from fibroblasts induced by small molecule compounds under hypoxia for treatment of Parkinson’s disease in rats
(2022-11-01)
9.
TMEM16F may be a new therapeutic target for Alzheimer’s disease
(2022-08-29)
10.
The Alzheimer’s disease-associated gene TREML2 modulates inflammation by regulating microglia polarization and NLRP3 inflammasome activation
(2022-07-20)
11.
Lactoferrin modification of berberine nanoliposomes enhances the neuroprotective effects in a mouse model of Alzheimer’s disease
(2022-06-17)
12.
DL-3-n-butylphthalide alleviates motor disturbance by suppressing ferroptosis in a rat model of Parkinson’s disease
(2022-06-17)
13.
Lamotrigine protects against cognitive deficits, synapse and nerve cell damage, and hallmark neuropathologies in a mouse model of Alzheimer’s disease
(2022-06-17)
14.
Icariin ameliorates memory deficits through regulating brain insulin signaling and glucose transporters in 3×Tg-AD mice
(2022-06-17)
15.
Dysregulated expression and distribution of Kif5α in neurites of wobbler motor neurons
(2022-06-17)
16.
Aquaporin 4 deficiency eliminates the beneficial effects of voluntary exercise in a mouse model of Alzheimer’s disease
(2022-03-10)
17.
Abnormal characterization of dynamic functional connectivity in Alzheimer’s disease
(2022-03-10)
18.
Endocannabinoid metabolism and Alzheimer’s disease
(2022-03-10)
19.
Glucose metabolism in amyotrophic lateral sclerosis: it is bitter-sweet
(2022-03-10)
20.
The blood-brain barrier models to study apolipoprotein E genotypes in Alzheimer’s disease
(2022-03-10)
21.
Perspective on the relationship between microbiota dysbiosis and neuroinflammation: probiotics as a treatment option
(2022-03-10)
22.
Is there a window of opportunity for the therapeutic use of vitamin D in multiple sclerosis?
(2022-03-10)
23.
Repurposed anti-cancer epidermal growth factor receptor inhibitors: mechanisms of neuroprotective effects in Alzheimer’s disease
(2022-03-10)
24.
Role of exosomes in the pathogenesis of inflammation in Parkinson’s disease
(2022-03-10)
25.
Intranasal neprilysin rapidly eliminates amyloid-beta plaques, but causes plaque compensations: the explanation why the amyloid-beta cascade may fail?
(2022-03-10)
26.
Crry silencing alleviates Alzheimer’s disease injury by regulating neuroinflammatory cytokines and the complement system
(2022-02-08)
27.
Phosphoinositide-3-kinase regulatory subunit 4 participates in the occurrence and development of amyotrophic lateral sclerosis by regulating autophagy
(2022-01-12)
28.
Propagation of TDP-43 proteinopathy in neurodegenerative disorders
(2022-01-12)
29.
Vibrotactile coordinated reset stimulation for the treatment of Parkinson’s disease
(2022-01-12)
30.
Impact of alpha-synuclein pathology on adult neurogenesis: evidence for multilayered mechanisms
(2022-01-12)
31.
Is activation of GDNF/RET signaling the answer for successful treatment of Parkinson’s disease? A discussion of data from the culture dish to the clinic
(2022-01-12)
32.
All roads lead to Rome — a review of the potential mechanisms by which exerkines exhibit neuroprotective effects in Alzheimer’s disease
(2021-12-17)
33.
Liposome based drug delivery as a potential treatment option for Alzheimer’s disease
(2021-12-17)
34.
Facial reanimation with interposition nerve graft or masseter nerve transfer: a comparative retrospective study
(2021-12-09)
35.
HOXA11-AS aggravates microglia-induced neuroinflammation after traumatic brain injury
(2021-12-09)
36.
Brief electrical nerve stimulation enhances intrinsic repair capacity of the focally demyelinated central nervous system
(2021-12-08)
37.
Repurposing verapamil for prevention of cognitive decline in sporadic Alzheimer’s disease
(2021-12-08)
38.
Significance of intercellular communication for neurodegenerative diseases
(2021-12-08)
39.
Deuterated dextromethorphan/quinidine for agitation in Alzheimer’s disease
(2021-12-08)
40.
Amyotrophic lateral sclerosis, a neurodegenerative motor neuron disease with retinal involvement
(2021-12-08)
跳至
页
第1页
共6页
共217条记录
首页
上一页
下一页
尾页